Biota Holdings (BTA-AU)

QUOTE AND NEWS
Benzinga  Mar 3  Comment 
Biota Pharmaceuticals, Inc. (Nasdaq: BOTA) announced today that it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir. The goal of the study is to enroll approximately 150 laboratory-confirmed human rhinovirus (HRV)...
GenEng News  Feb 26  Comment 
Biota Pharmaceuticals said today it will acquire Anaconda Pharma for up to $38 million, in a deal designed to grow the buyer’s infectious disease pipeline with a Phase II antiviral indicated for two diseases caused by human papillomavirus...
TheStreet.com  Feb 9  Comment 
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.  TheStreet Ratings quantitative algorithm...
Benzinga  Aug 4  Comment 
Analysts at Deutsche Bank downgraded Diamond Offshore Drilling (NYSE: DO) from Hold to Sell. The target price for Diamond Offshore Drilling has been lowered from $60.00 to $34.00. Diamond Offshore Drilling's shares closed at $47.32 on...
FierceBiotech  Aug 1  Comment 
Biota Pharmaceuticals' slow trip downward continued Friday as the company disclosed that its its lead program, a flu treatment called laninamivir octanoate, failed to beat out placebo in a midstage study, sending its shares to an all-time nadir.
StreetInsider.com  Aug 1  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Biota+Pharmaceuticals+%28BOTA%29+Reports+LANI+Met+Primary+Endpoint+in+Phase+2/9711812.html for the full story.
FierceBiotech  Jun 4  Comment 
The news out of Biota Pharmaceuticals has been a steady drumbeat of defeat, setbacks and layoffs for the past two years. And this week the dirge grew even louder with the announcement that the biotech company is slashing the bulk of its staff...





You may also be interested in articles related to Biota Holdings (BTA-AU):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki